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ABSTRACT
Background: Elderly patients with primary colorectal
cancer (CRC) are less frequently treated with adjuvant
chemotherapy than younger patients due to concerns
regarding toxicity and efficiency. We investigated how
age, performance status (PS) and comorbidity
influence treatment outcomes.
Patients and methods: A retrospective single-centre
study of 529 patients with stages II–III CRC treated
with adjuvant chemotherapy (5-fluorouracil/
capecitabine+/÷oxaliplatin) from 2001 to 2011 at
Herlev Hospital, Denmark. Baseline characteristics,
chemotherapy and outcome were analysed with respect
to age after adjusting for PS and comorbidity.
Results: Elderly patients (>70 years) had significantly
more comorbidity (p<0.001) and poorer PS (p=0.001)
than younger patients. Elderly were more frequently
treated with single-agent therapy (p=0.001) and at
lower initial dose (p<0.001). There was no age-
dependent difference in 3-year disease-free survival
(DFS; HR 1.09, 95% CI 0.80 to 1.47, p=0.59), in grade
3–5 toxicity (29% vs 28%, p=0.86) or in 10-year CRC
mortality (28%, HR 1.07, p=0.71). In elderly patients, a
reduction in chemotherapy dose intensity compared
with full dose had no impact on DFS or CRC mortality.
Elderly patients receiving <50% of planned cycles had
shorter DFS (HR=1.78, p=0.020) and higher CRC
mortality (HR=2.17, p=0.027) than elderly receiving all
cycles. Poor PS in younger and elderly patients was
related to shorter DFS (HR=1.95, p=0.002; HR=1.6,
p=0.035, respectively) and overall survival (OS;
HR=2.28, p<0.001; HR=2.03, p=0.002). Comorbidity in
younger patients was significantly related to shorter
DFS (HR 2.72, p<0.001), OS (HR 3.16, p<0.001) and
higher CRC mortality (HR 2.70, p=0.001).
Conclusions: Choice of regimen, primary dose
reduction and given dose intensity in patients treated
with adjuvant chemotherapy for CRC were highly
dependent on age. However, age had no impact on
DFS and CRC mortality. Comorbidity in younger
patients and PS in all patients were associated with
shorter DFS and higher CRC mortality.
INTRODUCTION
The incidence of colorectal cancer (CRC)
increases with age.1 2 Since populations are
getting older,3 more elderly patients will be
diagnosed with CRC. Adjuvant chemother-
apy with 5-fluorouracil (5-FU) or capecita-
bine after surgery for colon cancer (CC)
stages II–III reduces recurrence rate and
improves overall survival (OS).4 5 For elderly
patients, adjuvant chemotherapy prolongs
time to recurrence,6 and OS is higher in
Key questions
What is already known about this subject?
▸ Elderly patients treated with adjuvant chemother-
apy for colorectal cancer (CRC) are at greater
risk of treatment related toxicity than younger
patients. There are no precise guidelines for
treating the elderly patients, but age is inde-
pendently associated with reduced primary
dose, to reduce risk of toxicity. A lower dose,
however, might lead to an inefficient treatment
with a greater risk of relapse.
What are the new findings?
▸ In the ACCORE study choice of regimen and
given dose intensity of adjuvant chemotherapy
were highly dependent on age. However, age
had no impact on disease-free survival (DFS)
and CRC mortality. Comorbidity in younger
patients and performance status in all patients
were associated with shorter DFS and higher
CRC mortality. No difference was found in DFS
or CRC-related mortality in elderly patients who
had undergone only 50% of all cycles compared
to elderly patients who had received all cycles.
Receiving reduced dose intensities compared to
full dose intensity had no impact on cancer
prognosis in elderly patients.
How might this impact on clinical practice?
▸ The results suggest that lower dose intensity
and fewer numbers of cycles could be sufficient
adjuvant treatment for elderly patients with CRC.
With a lower risk of toxicity, more frail elderly
patients might receive treatment, with a reduced
risk of recurrence and better prognosis for
elderly patients as a result.
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patients with CC >75 years receiving adjuvant chemo-
therapy.7 8 Although the benefit of single-agent treat-
ment seems to be the same in elderly and younger
patients, elderly patients are less frequently treated with
adjuvant chemotherapy.9 In 5489 patients operated on
for stage III CC, 63% of the patients aged 75–79 years
received adjuvant chemotherapy, whereas only 14% of
patients ≥85 years received treatment.7 Combination
chemotherapy is considered standard therapy for
patients with stage III CC, but in elderly patients the
beneficial effect on disease-free survival (DFS) and OS
of adding oxaliplatin to 5-FU/capecitabine is controver-
sial.4 10–14
Many elderly patients with CRC are not treated with
adjuvant chemotherapy because of high age, comorbidity,
poor performance status (PS),8 or due to lack of social
support and concerns regarding toxicity and efficiency.
Elderly patients tend to receive no or less aggressive treat-
ment, which could explain the higher rates of recurrence
and the higher mortality seen in these patients.2 More
information is needed in how comorbidity and PS influ-
ence treatment outcomes in elderly patients with CRC.
We investigated age-dependent differences and the
role of PS and comorbidity in relation to type of
regimen, dose intensity, number of cycles, toxicity, and
time to recurrence and death in patients treated with
adjuvant chemotherapy after radical resection of stage
II–III CRC. We also searched for clinical biomarkers that
could identify frail elderly patients with a high risk of
toxicity and poor prognosis.
METHODS
This is a retrospective single-centre study evaluating the
efficacy and toxicity of adjuvant chemotherapy in
patients who underwent radical resection and chemo-
therapy for primary CRC at the Department of
Oncology, Herlev Hospital, Denmark, from January 2001
to January 2012. During this period, the adjuvant treat-
ment given to patients with colon and rectum cancer
was similar, that is, 6 months of 5-FU or capecitabine
+/÷oxaliplatin (for details see online supplementary
table S1).
Patients
Among patients planned to start adjuvant chemotherapy
after surgery for CRC, 849 medical charts were reviewed
and assessed for eligibility. Data were extracted and inter-
preted by one author (CML). Overall 320 patients were
excluded, and 529 patients were found eligible for the
present study (see online supplementary figure S2).
Baseline characteristics included demographic data,
comorbidities, body mass index (BMI), tobacco use, civil
status, PS, tumour characteristics and blood samples (see
online supplementary table S1). Cause of death was cate-
gorised into CRC mortality, other causes of death or
unknown cause. Adverse events were interpreted accord-
ing to the National Cancer Institute Common Toxicity
Criteria (CTCAE) V.3.0. Grades 3–5 were defined as
severe toxicity.
The statistical methods are described in detail in the
online supplementary text S3.
RESULTS
A total of 529 patients were included and divided into
elderly patients (≥70 years, N=191) and younger patients
(<70 years, N=338). Clinical and histopathological base-
line characteristics are given in table 1. The mean
follow-up for the two groups was 6.34 years (3 days to
13.80 years) for the younger group and 5.40 years
(20 days to 13.75 years) for the elderly group. Elderly
patients had significantly poorer PS and more comorbid-
ity than the younger group. Data were therefore systemat-
ically analysed with and without adjustment for PS and
comorbidity. The elderly patients were more likely to live
alone and have right-side tumours than younger patients.
Treatment, doses and compliance of chemotherapy
Choice of single-agent or combination treatment was asso-
ciated with age (see online supplementary figure S2). The
odds of receiving single-agent therapy increased by 10.6%
per year from the age of 65 years (see online
supplementary figure S4). The likelihood of receiving
reduced primary dose was significantly higher for the
elderly patients before and after adjustment for PS and
comorbidity (OR 6.92, 95% CI 3.54 to 13.52, p<0.001).
Patients given primary dose reduction had a significantly
higher median age (76 vs 64, p<0.001), poorer PS
(p<0.001) and more comorbidity (p<0.001) than patients
receiving full dose chemotherapy (table 1).
The proportion of patients receiving a full cumulative
dose of capecitabine was similar in elderly and younger
patients, but elderly patients were less likely to receive full
dose of 5-FU (OR 0.20, p=0.02) and oxaliplatin in the
Folfox regimen (OR 0.43, p=0.03) after adjustment for PS
and comorbidity (see online supplementary table S5).
The percentage of patients receiving all cycles of cape-
citabine and 5-FU was similar in the two groups. Elderly
patients were less likely to receive all cycles of oxaliplatin
in the Capeox regimen (OR 0.47, p=0.04), but after
adjusting for PS and comorbidity, the difference was not
significant (see online supplementary table S6).
The distributions of dose intensity and compliance are
given in online supplementary figure S7.
Adverse events
The prevalence of toxicity is shown in online
supplementary table S8. Toxicity (grades 3–5) was
similar in the two groups (29% vs 28%, p=0.86). Death
due to toxicity was observed in one elderly patient
(0.52%) and in three younger patients (0.89%). There
was no age-dependent difference in hospitalisations
(rate ratio (RR) 1.09, p=0.79) or length of hospital stay
(RR 0.87, p=0.13) between the two age groups.
Diagnoses causing hospitalisation were similar in
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Table 1 Baseline characteristics
Age groups Start dose
Characteristics Missing
<70 years N (%)
N=338
≥70 years N (%)
N=191 p Value
100% N (%)
N=459
≤75% N (%)
N=67 p Value
Age 0 Median (range) 61 (31–69) 74 (70–85) 64 (31–82) 76 (44–85) <0.001
Sex 0 F 161 (48) 95 (50) 0.71 212 (46) 41 (61) 0.03
M 177 (52) 96 (50) 247 (54) 26 (39)
PS 60 0 250 (85) 125 (71) 0.001 337 (84) 35 (56) <0.001
1 40 (14) 44 (25) 60 (15) 24 (38)
2+ 4 (1) 6 (3) 6 (1.5) 4 (6.4)
Civil status 31 Alone 72 (23) 62 (34) 0.007 113 (26) 19 (29) 0.73
Married 245 (77) 119 (66) 317 (74) 46 (71)
BMI 136 Median (range) 24.3 (16.5–45.3) 23.9 (17–49.8) 0.11 24.2 (17–49.8) 23.9 (16.5–32.6) 0.52
Number of comorbidities 0 0 166 (49) 45 (24) <0.001 197 (43) 12 (18) <0.001
1 89 (26) 67 (35) 134 (29) 22 (33)
2 42 (12) 44 (23) 70 (15) 16 (24)
3 22 (7) 23 (12) 31 (6.8) 13 (19)
4+ 19 (6) 12 (6) 27 (5.9) 4 (6.0)
Smoking 44 Non-smoker 154 (50) 90 (51) 0.86 205 (49) 37 (60) 0.14
Smoker 155 (50) 86 (49) 215 (51) 25 (40)
Surgery 19 Elective 256 (79) 140 (76) 0.60 344 (78) 49 (77)
Acute 70 (21) 44 (23) 99 (22) 15 (23)
Tumour location* 0 Right 128 (38) 98 (51) 0.009 210 (46) 26 (39) 0.12
Left 163 (48) 75 (39) 60 (13) 5 (7.5)
Rectum 47 (14) 18 (9) 189 (41) 36 (54)
Tumour stage† 24 II 44 (14) 26 (14) 0.97 62 (14) 8 (12) 0.83
III 278 (86) 157 (86) 375 (86) 57 (88)
MSI 265 Instability 20 (12) 16 (17) 0.34 31 (14) 5 (13) 1.00
White cell counts 50 Median (range) 6.8 (2.8–22.8) 7.2 (3.4–19.8) 0.04 6.8 (2.8–23) 7.4 (4.1–18) 0.02
Neutrophils 55 Median (range) 4.38 (1.68–82) 4.88 (1.61–84) 0.05 4.44 (1.6–84) 5.2 (2.4–81) 0.21
Lymphocytes 54 Median (range) 1.91 (0.56–45) 1.75 (0.46–37) 0.02 1.9 (0.6–45) 1.6 (0.46–15) 0.003
Haemoglobin 48 Median (range) 7.9 (5.5–10.8) 7.6 (5.8–10,5) 0.046 7.9 (5.6–11) 7.5 (5.5–11) 0.01
Platelets 53 Median (range) 333 (127–1080) 323 (131–1310) 0.11 328 (127–1310) 331 (139–833) 0.75
LDH 57 Median (range) 174 (84–894) 179 (106–640) 0.09 177 (84–894) 172 (105–389) 0.45
CEA 133 Median (range) 1.5 (0.3–84.4) 1.6 (0.3–90.2) 0.17 1.5 (0.3–90) 1.7 (0.5–26) 0.95
Creatinine 50 Median (range) 76 (46–292) 79 (50–209) 0.06 77 (46–292) 78 (51–167) 0.04
*Right=proximal colon, left=distal colon.
†Stage II: T3–T4 N=0, stage III: T1–T4 and N1–N2.
BMI, body mass index; CEA, carcino embryonic antigen; F, female; LDH, lactate dehydrogenase; M, male; MSI, microsatelite instability; PS, performance status.
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younger and elderly patients (see online supplementary
table S9).
Outcomes
There was no significant difference in 3-year DFS in the
two age groups (HR 1.09, p=0.59). Seventy per cent of
the elderly patients with PS=0 and 55% of the elderly
with PS+1 were disease free and alive at 3 years (see
online supplementary figure S10). The corresponding
numbers for younger patients were 70% (PS=0) and
60% (PS+1), respectively. Figure 1A, B illustrates that
10-year DFS was also similar in both age groups.
In addition, 2-year OS was similar (HR=1.16, p=0.53).
At 2 years, 90% of the elderly patients with PS=0 and
80% of the elderly with PS+1 were alive. The corre-
sponding numbers for younger patients were 90%
(PS=0) and 75% (PS+1; see online supplementary figure
S10). Figure 1C, D suggests a small difference in the
10-year OS between the two age groups, PS=0. After
adjustment for PS and comorbidity, no significant differ-
ence existed in 10-year survival between the age groups
(HR 1.35, p=0.051). The 10-year CRC mortality was iden-
tical in the two groups (HR=1.03, p=0.88), but elderly
patients had a higher mortality due to other causes of
death, also after adjustment for PS and comorbidity
(HR=1.83, p=0.02; figure 2).
Baseline correlation analyses
For both elderly and younger patients, poor PS was signifi-
cantly correlated with shorter DFS (see online
supplementary table S11) and shorter OS (see online
supplementary table S12). In younger patients, poor PS was
Figure 1 Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients
treated with adjuvant chemotherapy after surgery for stages II–III CRC. The patients are divided into elderly (≥70 years, grey)
and younger (<70 years, black). CRC, colorectal cancer; DFS, disease-free survival; OS, overall survival; PS, performance
status.
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also related to both cancer-related mortality (see online
supplementary table S13) and death from other causes
(see online supplementary table S14). The effect of poor
PS on hospitalisation was significantly larger in elderly than
in younger patients (p=0.041; online supplementary table
S15). High comorbidity in younger patients but not in
elderly patients was significantly associated with shorter
DFS (see online supplementary table S11), shorter OS (see
online supplementary table S12), cancer-related mortality
(see online supplementary table S13) and other causes of
death (see online supplementary table S14). The effect of
comorbidity on OS was significantly greater in younger
than in elderly patients (p=0.022).
Overweight (BMI 25–30) was after adjustment for PS
and comorbidity significantly correlated with shorter
DFS in elderly patients (see online supplementary
table S11).
High serum carcino embryonic antigen in elderly and
younger patients was related to shorter DFS, shorter OS
and higher cancer-related mortality (see online
supplementary tables S11–S13). Elevated serum lactate
dehydrogenase and high white cell count (WCC) were
associated with shorter DFS and OS (see online
supplementary tables S11 and S12). High WCC in the
younger patients were also associated with severe toxicity
(see online supplementary table S16).
Treatment-related analyses
For elderly patients, combination therapy compared
with single-agent therapy was related to longer DFS (HR
0.58, p=0.016; see online supplementary table S17) and
longer OS (HR 0.49, p=0.003; see online supplementary
table S16) and this difference was significantly different
from younger patients (page=0.04).
Figure 2 The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant
chemotherapy after surgery for stages II–III CRC. The patients are divided into elderly (≥70 years, grey) and younger
(<70 years, black). CRC, colorectal cancer; DFS, disease-free survival; OS, overall survival; PS, performance status.
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Elderly patients receiving <50% of planned cycles of
capecitabine/5-FU had shorter DFS (HR=1.78, p=0.020;
see online supplementary table S17), shorter OS
(HR=2.12, p=0.003; see online supplementary table S18)
and higher CRC-related death (HR=2.17, p=0.028; see
online supplementary table S19) than elderly patients
given all cycles.
Younger patients receiving <75% of planned cycles of
capecitabine/5-FU had shorter DFS (HR=2.24, p=0.017;
see online supplementary table S17), shorter OS
(HR=2.80, p=0.003; see online supplementary table S18)
and higher CRC-related death (HR=3.26, p=0.001; see
online supplementary table S19) than younger patients
given all cycles. Furthermore, younger patients receiving
dose intensity below 50% compared with dose intensity
>90% had higher CRC mortality (HR=3.15, p=0.02; see
online supplementary table S19).
A higher rate of severe toxicity was observed in elderly
and younger patient receiving combination therapy
compared with single-agent therapy (HR=3.69, p=0.001
and HR=2.28, p=0.006, respectively; see online
supplementary table S19).
DISCUSSION
In the present study, we investigated the age-dependent
(<70 vs ≥70 years) difference in adjuvant chemotherapy
and outcomes in patients who underwent radical
surgery for stages II–III CRC). The cut-off at 70 years is
also used in international treatment guidelines15 and is
frequently used in the literature and made it possible to
compare our results to other relevant studies.10 13 15
These two age groups were, as expected, not compar-
able, a higher degree of comorbidity and poor PS being
seen in the elderly group. There was also a difference in
tumour localisation: elderly right-sided, younger group
left-sided dominance. The elderly patients were also
more likely to live alone, which is known to be a prog-
nostic factor for poorer OS.16 17
In the elderly group receiving combination therapy
compared with single-agent therapy was related to
higher DFS and OS, but not to death due to CRC. A
longer DFS in both age groups treated with combination
chemotherapy suggests that oxaliplatin was also effective
in the elderly. This is in contrast to other findings,10
only a small beneficial effect of oxaliplatin being seen in
patients >75 years.7 This speaks in favour of giving
single-agent chemotherapy to frail elderly and combin-
ation therapy to fit elderly patients.
We found that the primary dose of adjuvant chemo-
therapy was significantly lower in elderly patients, who
also had more comorbidity and poorer PS. Interestingly,
primary dose reduction had no significant impact on
DFS or CRC-related death. Age-based primary dose
reduction is not routinely recommended, but older age
is independently associated with primary dose reduction
in patients with solid tumours.18 However, a reduction in
toxicity, hospitalisation or discontinuation of therapy was
not found in this study in relation to age.
In our study, elderly patients received a lower dose
intensity of 5-FU and oxaliplatin, but with no impact on
DSF, OS and CRC mortality. These results support other
findings; adjustments in dose intensity and regimens still
have a survival benefit in elderly patients.8
We found that the number of received cycles
significantly correlated with survival. Younger patients
who received <75% of planned cycles had a shorter
DFS and OS and higher CRC-related death. However, no
significant difference was seen between 75% of planned
cycles and full treatment. Elderly patients who received
<50% of planned cycles had higher CRC mortality. Our
results are consistent with Kim et al,19 who found that sur-
vival was better in patients receiving at least 75% of
expected cycles, but dose intensity below 75% did not
affect OS. These results suggest that primary dose reduc-
tion in all elderly patients may improve the chance of
completing the treatment regimen, but one should be
cautious with making this conclusion based on this retro-
spective data which is a limitation of this study. Therefore,
we need randomised control trials including frail elderly
patients to illuminate this clinical issue.
In the literature, only 50% of patients with stages II–III
CRC complete 6 months’ adjuvant treatment.20 21 In the
large ongoing SCOT study, more than 6000 patients
included,22 the efficiency of 3 months’ oxaliplatin-based
adjuvant chemotherapy is compared with 6 months’ stand-
ard treatment. The survival data are expected in 2017.
Our retrospective single-centre study has several
strengths. One researcher (CML) collected and inter-
preted all data to minimise interpersonal bias. We
assessed both cancer-related mortality and other causes
of death. This is crucial in evaluating the effect of
chemotherapy in elderly patients, who have a higher
overall mortality. Study limitations include small sample
size in subanalyses of adverse effects. Data were collected
from 2001 to 2012, and analysis of some clinical biomar-
kers was not undertaken during the first period (eg,
tumour characteristics, RAS and BRAF mutation status,
and presence of microsatellite instability). The follow-up
programme only every sixth month might have delayed
discover of recurrence.
Only patients receiving at least one dose of chemother-
apy were assessed for eligibility in our study. Thus, many
frail and elderly people were excluded from the start,
perhaps accounting for the low occurrence of grades 3–5
toxicity (<30%) found in the ACCORE study compared
with other studies.8 19 At the same time, frail and elderly
patients more frequently received single-agent therapy and
primary reduced doses, which probably have decreased
the occurrence of toxicity, but without affecting the
outcome. Despite the fact that the elderly patients more
frequently received single-agent therapy (selection bias),
their DFS and CRC mortality were similar to the younger
patients. In accordance with Sanoff et al,23 we found no
increased hospitalisation among older patients. Hamza
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et al24 found a similar low occurrence of severe toxicity
among patients below and above 70 years but presented
no data on DFS or cancer-specific mortality. No excess tox-
icity was found in patients with CC ≥75 years with good PS
and no comorbidity.21
We suggest that treatment decisions, including dose
intensity and choice of regimen, should not be made
according to chronological age alone. Patients should be
assessed with a combination of different measures like
PS, comorbidities, functional and psychocognitive status,
and risk of recurrence.15
In conclusion, we found an age-dependent difference in
choice of chemotherapy regimen, primary dose reduction
and given dose intensity. Interestingly, no age-dependent
differences in DFS or CRC-related mortality were observed,
but comorbidity and PS were related to shorter DFS and
higher CRC mortality. To maintain (optimise) treatment
efficacy and minimise toxicity, we need randomised control
trials that include frail elderly patients and investigate
optimal dose and number of treatments.
Our results generate the hypothesis ‘in adjuvant
chemotherapy for primary CRC in elderly patients
primary dose reduction to 75% is as effective as full dose
treatment but with an expected decrease in toxicity as a
result’. We suggest a randomised controlled trial com-
paring full dose to primary dose reduction (75%) in
elderly patients with comorbidity and functional decline.
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